Development of Test System for Detection of V617F Mutation of JAK2 Gene in Patients with Chronic Myeloproliferative Disorders

1Dybkov, MV, 2Gartovska, IR, 1Telegeev, GD, 1Maliuta, SS
1Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv
2Hematology Department of the Kiev regional oncologic dispensary Ministry of Health of Ukraine, Kyiv
Nauka innov. 2009, 5(6):59-63
Section: Scientific and Technical Innovative Projects of National Academy of Sciences of Ukraine
Language: Ukrainian
V617F mutation of jak2 gene is an important diagnostic criterion for chronic myeloproliferative disorders. The testsystem for detection of the mutation by using the method of reverse transcription polymerase chain reaction and direct sequencing of PCR products was proposed.
Keywords: diagnostics, JAK2, myeloproliferative disorders, PCR, V617F
1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951. V. 6. P. 372-375.
2. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neo plasms. Blood. 2002. V. 100. P. 2292-2302.
3. Baxter E.J., Scott L.M., Campbell P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005. V. 365, N 9464. P. 1054-1061.
4. Kralovics R., Passamonti F., Buser A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005. V. 352, N 17. P. 1779-1790.
5. Levine R.L., Wadleigh M., Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005. V. 7, N 4. P. 387-397.
6. Zhao R., Xing S., Li Z. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005. V. 280, N 24. P. 22788-22792.
7. James C., Ugo V., Le Couedic J.P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005. V. 434. P. 1144-1148.
8. Scott L.M., Tong W., Levine R.L. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007. V. 356, N 5. P. 459-468.
9. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008. V. 22. P. 14-22.
10. Spivak J.L., Silver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008. V. 112, N 2. P. 231-239.
11. Chomczynski P., Sacchi N. Single-step method of RNA iso lation by acid guanidinum thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 1987. V. 162. P. 156-159.
12. Telegejev G.D., Dybkov M.V., Bozhko M.V. ta in. Monitoryng hronichnogo mijelolejkozu za dopomogoju molekuljarno-biologichnyh metodiv (metodychni rekomendacii'). Respublikans'kyj centr naukovo-medychnoi' informacii'. Kyi'v, 1997 [in Ukrainian].
13. Hussein K., Bock O., Seegers A., Flasshove M. et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007. V. 109, N 9. P. 4106-4107.
14. Bocchia M., Vannucchi A.M., Gozzetti A. et al. Insights into JAK2–V617F mutation in CML. Lancet Oncol. 2007. V. 8. P. 864-866.